Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. cut its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 34.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,262,837 shares of the company's stock after selling 1,699,384 shares during the period. Pacer Advisors Inc. owned 7.07% of Pacira BioSciences worth $61,472,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its position in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after buying an additional 2,749 shares during the period. Virtus Investment Advisers Inc. acquired a new position in shares of Pacira BioSciences in the third quarter valued at approximately $98,000. CWM LLC increased its stake in Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company's stock worth $98,000 after buying an additional 5,716 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company's stock worth $134,000 after buying an additional 3,404 shares in the last quarter. Finally, Quest Partners LLC boosted its position in Pacira BioSciences by 137.6% in the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company's stock valued at $142,000 after buying an additional 5,449 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PCRX has been the subject of a number of recent research reports. Royal Bank of Canada reiterated a "sector perform" rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC upped their target price on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Barclays decreased their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a research note on Tuesday, November 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $24.50.

Pacira BioSciences Stock Performance

Shares of PCRX stock traded up $0.09 during mid-day trading on Tuesday, hitting $25.75. 1,138,609 shares of the stock were exchanged, compared to its average volume of 877,153. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $34.01. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -12.68 and a beta of 0.76. The stock's fifty day simple moving average is $19.70 and its two-hundred day simple moving average is $17.58.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.